Connect with us

Profiles

Jose Baselga – What Happened To Him!

Published

on

Popular Spanish medical oncologist and researcher, Jose Baselga is dead. He passed away today March 21 2021 at the age of 61.

No cause of death has been reported yet as of the time of filing this report but Spanish newspaper La Vanguardia reported that he died of Creutzfeldt-Jakob disease, a rapidly evolving degenerative neurological disorder.

Jose’s death news was announced by AstraZeneca, the company he had worked as executive vice president for research and development in oncology.

Who Is Jose Baselga?

Born in Barcelona, Jose Baselga was a Spanish medical oncologist and researcher who from 1959 till January 2019 had served as director of the Oncology Research and Development Unit of the AstraZeneca company.

He was also medical director of the Memorial Sloan-Kettering Cancer Center in New York until September 2018 -one of the most prestigious centres for clinical research related to cancer-, a position from which he resigned after the publication of information from ‘The New York Times and ‘ProPublica’ in which they accused the doctor of having received millionaire aid from the pharmaceutical industry without having reflected it in their research work, as is mandatory in the United States. The oncologist justified it as a failure.

He also served as Chief of the Division of Hematology-Oncology and Associate Director of the Massachusetts General Hospital Cancer Center and was Professor of Medicine at Harvard Medical School.

Jose’s research has led to substantial improvements in survival for patients with multiple types of breast cancer.

He founded the Vall d’Hebron Institute of Oncology at Vall d’Hebron University Hospital in Barcelona.

Dr Jose Resignation After Receiving $1.5M

Dr Jose Baselga took a decision in 2018 to resign as Chief medical officer after receiving $1.5M payments for-profit health care companies from the Memorial Sloan Kettering.

According to reports from a news article posted online, Jose resigned his position in the company over his failure to disclose payments from health care companies in dozens of research articles he wrote.

After his resignation from the Memorial Sloan Kettering Baselga was appointed as an executive at the pharmaceutical company AstraZeneca, where he oversees the development of its cancer drugs.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Advertisement

SPORTS

ENTERTAINMENT

HOT NOW!